ES2171086T3 - Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica. - Google Patents
Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica.Info
- Publication number
- ES2171086T3 ES2171086T3 ES99926330T ES99926330T ES2171086T3 ES 2171086 T3 ES2171086 T3 ES 2171086T3 ES 99926330 T ES99926330 T ES 99926330T ES 99926330 T ES99926330 T ES 99926330T ES 2171086 T3 ES2171086 T3 ES 2171086T3
- Authority
- ES
- Spain
- Prior art keywords
- medicines
- preparation
- cytotoxic activity
- hmg proteins
- hmg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Uso de una proteína del grupo HMG,un fragmento de la misma o un péptido con secuencia de aminoácidos que corresponde o deriva de la secuencia de HMG para la preparación de medicamentos antitumorales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98MI001094A IT1299583B1 (it) | 1998-05-19 | 1998-05-19 | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2171086T3 true ES2171086T3 (es) | 2002-08-16 |
Family
ID=11380053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99926330T Expired - Lifetime ES2171086T3 (es) | 1998-05-19 | 1999-05-19 | Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1079849B1 (es) |
| JP (1) | JP2002515445A (es) |
| AT (1) | ATE211391T1 (es) |
| AU (1) | AU4363199A (es) |
| DE (1) | DE69900756T2 (es) |
| DK (1) | DK1079849T3 (es) |
| ES (1) | ES2171086T3 (es) |
| IT (1) | IT1299583B1 (es) |
| PT (1) | PT1079849E (es) |
| WO (1) | WO1999059609A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| JP4945876B2 (ja) * | 2000-04-05 | 2012-06-06 | 東レ株式会社 | ハイモビリティーグループタンパクの吸着材および体液浄化カラム |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| ITMI20011986A1 (it) * | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| DE50212280D1 (de) * | 2001-12-19 | 2008-06-26 | Alcedo Biotech Gmbh | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren |
| GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| EP1668035A2 (en) | 2003-09-11 | 2006-06-14 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| WO2007001422A2 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
| WO2007076200A2 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Inc. | Antagonists of hmgb1 and/or rage and methods of use thereof |
| DK2525817T3 (en) | 2010-01-21 | 2017-10-02 | Univ Arkansas | Vaccine vectors and methods for enhancing immune responses |
| NZ604412A (en) | 2010-06-09 | 2015-01-30 | Univ Arkansas | Vaccine and methods to reduce campylobacter infection |
| EA030929B1 (ru) | 2013-02-14 | 2018-10-31 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас | КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria |
| HK1219045A1 (zh) | 2013-03-15 | 2017-03-24 | The Board Of Trustees Of The University Of Arkansas | 增强对肠道病原体免疫应答的组合物和方法 |
| BR112018072592A2 (pt) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62166897A (ja) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
| EP0727487A1 (en) * | 1995-02-17 | 1996-08-21 | K.U. Leuven Research & Development | Multiple-tumor aberrant growth genes |
| FR2739292B1 (fr) * | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations |
| JP3018313B2 (ja) * | 1996-02-23 | 2000-03-13 | 雪印乳業株式会社 | 骨形成促進及び骨吸収防止剤 |
-
1998
- 1998-05-19 IT IT98MI001094A patent/IT1299583B1/it active IP Right Grant
-
1999
- 1999-05-19 ES ES99926330T patent/ES2171086T3/es not_active Expired - Lifetime
- 1999-05-19 DE DE69900756T patent/DE69900756T2/de not_active Expired - Fee Related
- 1999-05-19 JP JP2000549273A patent/JP2002515445A/ja active Pending
- 1999-05-19 AT AT99926330T patent/ATE211391T1/de not_active IP Right Cessation
- 1999-05-19 PT PT99926330T patent/PT1079849E/pt unknown
- 1999-05-19 DK DK99926330T patent/DK1079849T3/da active
- 1999-05-19 EP EP99926330A patent/EP1079849B1/en not_active Expired - Lifetime
- 1999-05-19 AU AU43631/99A patent/AU4363199A/en not_active Abandoned
- 1999-05-19 WO PCT/EP1999/003431 patent/WO1999059609A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1079849B1 (en) | 2002-01-02 |
| PT1079849E (pt) | 2002-06-28 |
| DE69900756T2 (de) | 2003-03-13 |
| WO1999059609A2 (en) | 1999-11-25 |
| JP2002515445A (ja) | 2002-05-28 |
| AU4363199A (en) | 1999-12-06 |
| EP1079849A2 (en) | 2001-03-07 |
| IT1299583B1 (it) | 2000-03-16 |
| DK1079849T3 (da) | 2002-04-22 |
| DE69900756D1 (de) | 2002-02-28 |
| WO1999059609A3 (en) | 2000-01-27 |
| ATE211391T1 (de) | 2002-01-15 |
| ITMI981094A1 (it) | 1999-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2171086T3 (es) | Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica. | |
| ATE254630T1 (de) | Cyclosporine | |
| BR9713404A (pt) | ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos. | |
| EP0695171A1 (en) | GONADOTROPINE CONTAINING FREEZER DRIED DROPS | |
| BR9714517A (pt) | Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos | |
| PT848720E (pt) | Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros | |
| EA200000331A1 (ru) | Фармацевтические композиции, содержащие белок плазмы | |
| NO20010995D0 (no) | Cytotoksiske peptider modifisert med store eller lipofile rester | |
| DZ2509A1 (fr) | Analogues peptidiques de la lh-rh leur utilisationet les compositions pharmaceutiques les contenant. | |
| WO1999060013A3 (en) | Il-6 antagonist peptides | |
| CA2280875A1 (en) | Remedies for lymphocytic tumors | |
| DE69938935D1 (de) | Zyklische conotoxin-peptide | |
| ZA943920B (en) | Pharmaceutical compositions | |
| RU99107658A (ru) | Применение белков в качестве агентов против аутоиммунных заболеваний | |
| RU94040865A (ru) | Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью | |
| PL355852A1 (en) | Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients | |
| NO20000424D0 (no) | Streptograminer, deres fremstilling samt preparater inneholdende forbindelsene | |
| DE69434151D1 (de) | Therapeutische inhaltsstoffe | |
| BR9813102A (pt) | Derivados de ácido metilenobisfosfÈnico novos | |
| FI961505A0 (fi) | Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset peptidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset | |
| NO20023914L (no) | Preparater for anvendelse for regulering av aktiviteten til parkingenet | |
| BR9813037A (pt) | Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa | |
| AU2506188A (en) | Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance | |
| RU94046405A (ru) | Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок | |
| WO1998051295A1 (en) | Hiv-1 protease inhibitors, process for producing the same, and medicinal compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 1079849 Country of ref document: ES |